[Chronic HCV infections. A model disease for therapy, economics and social-medical aspects].
In Germany up to 800,000 persons are chronically infected with the hepatis C virus. This chronic disease is correlated with a significant morbidity and mortality. This is a consequence of the development of liver cirrhosis and hepatocellular carcinoma in a substantial proportion of the patients. Health quality of life is also affected by the infection. There are reliable standards available for diagnosis and treatment. Antiviral treatment is highly effective and the combination of pegylated interferon alpha with ribavirin leads to a sustained viral eradication in about 60% of the cases. The treatment is also cost-effective and results in an increased life expectancy. Costs for HCV treatment are favourable in comparison to other well accepted therapies and interventions and a reduction of future costs can be expected.Thus, active screening for HCV infected persons should be intensified to improve the quality of medical care. Early and broad treatment is potentially able to reduce the future burden of HCV-related diseases.
Rossol
S
S
Medizinische Klinik, Krankenhaus Nordwest, Frankfurt am Main, Germany. siegbert.rossol@khnw.de
D002908:Chronic Disease; D017281:Cost of Illness; D020000:Decision Support Systems, Clinical; D003695:Delivery of Health Care / Q000191:economics / Q000706:statistics & numerical data; D004196:Disease Outbreaks / Q000191:economics* / Q000517:prevention & control*; D005858:Germany / Q000453:epidemiology; D019698:Hepatitis C, Chronic / Q000191:economics* / Q000401:mortality / Q000628:therapy*; D006801:Humans; D018803:Models, Economic; D012936:Social Medicine